Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 31, 2005

Conditions
Pulmonary Disease, Chronic ObstructiveChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

SB681323

Trial Locations (17)

2400

GSK Investigational Site, København NV

20535

GSK Investigational Site, Hamburg

22927

GSK Investigational Site, Großhansdorf

55131

GSK Investigational Site, Mainz

82131

GSK Investigational Site, Gauting

DK-9100

GSK Investigational Site, Aalborg

00029

GSK Investigational Site, Helsinki

3317 NM

GSK Investigational Site, Dordrecht

5623 EJ

GSK Investigational Site, Eindhoven

6229 HX

GSK Investigational Site, Maastricht

3000 DR

GSK Investigational Site, Rotterdam

L9 7AL

GSK Investigational Site, Liverpool

LE3 9QP

GSK Investigational Site, Leicester

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne

BT9 6AB

GSK Investigational Site, Belfast

HU16 5JQ

GSK Investigational Site, Hull

E2 9JX

GSK Investigational Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY